<DOC>
	<DOCNO>NCT02079324</DOCNO>
	<brief_summary>The purpose research evaluate MTD , Safety efficacy GX-051 intratumoral injection head neck cancer patience .</brief_summary>
	<brief_title>Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head Neck Cancer</brief_title>
	<detailed_description>The primary purpose study determine MTD ( Maximum Tolerable Dose ) GX-051 administered tumor . The second purpose evaluate safety efficacy GX-051 .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Are capable understand complying requirement study sign informed consent ( ICF ) . Very advanced head neck cancer age 19 . Longest distance tumor big 1 cm capable Intratumoral injection . Baseline ECOG Performance Status 0 , 1 2 . Have life expectancy 6 month . Have history prior anticancer treatment . Female patient pregnant breast feeding , adult reproductive potential use effective birth control methods.Subject participate clinical trial treatment vaccine immunotherapy year . Have tumor near main vessel occur embolism injection hypervascularity . Patients currently receive anticancer immunotherapy Patients receive prior treatment stem cell therapy . Have autoimmune disease ( multiple sclerosis , systemic lupus erythromatosis , thyroiditis , psoriasis , inflammatory bowel disease etc. ) . Have Graft rejection reaction GVHD . Have immunodeficiency disease . Leukocytes &lt; 3.0 x109/L . Absolute neutrophil count &lt; 1.5x109/L . Platelet count &lt; 100 x 109/L . Have know positive test hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) . Alanine Aminotransferase ( ALT ) &gt; 2.5xUNL . Aspartate Aminotransferase ( AST ) &gt; 2.5xUNL . Total Bilirubin &gt; UNL . Have blood Creatinine &gt; UNL . Known allergy IL12 excipient ( ) study medication include fetal bovine serum . Second primary cancer Metastatic brain tumor meningioma . Have tumor near main artery . Uncontrolled hypertension . Uncontrolled diabetes uncontrolled ( arrhythmia ) . Heart failure ( NYHA Functional Class II ) ; unstable coronary artery disease ; myocardial infarction within 6 month . ChildPugh Class C hepatic impairment . Severe renal impairment ( creatinine clearance &lt; 30 ml/min ) dialysis . Have active infection history recurrent infection . Patients severe and/or uncontrolled medical condition condition could affect participation study . Are consider ineligible investigator due mental disease CNS disease . Administration tumor therapy , include chemotherapy radiotherapy within 4 week ( 6 week case nitrosoureas mytomycin C ) begin study treatment . Patients receive chronic , systemic treatment immunosuppressive agent ( steroid ) immunomodulator within 2 week prior screen . Have participate another clinical trial within 30 day prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>gene therapy</keyword>
	<keyword>stem cell therapy</keyword>
	<keyword>immunotherappy</keyword>
</DOC>